Oral Peptides: Absorption, Stability and What Studies Report

Oral peptides present a fundamental issue of pharmacology, since proteins and peptides are generally degraded in the stomach. At the same time, BPC-157 defies this rule and remains the focus of scientific inquiries. In this article, we will investigate the issue of bioavailability, available formats of oral compounds, the findings of studies devoted to oral BPC-157, and compare the effects of oral and injected delivery methods.

The Bioavailability Problem with Oral Peptides

Gastric Acid and Enzymatic Degradation

The stomach’s pH-level is estimated to be 1.5 to 3.5, which is sufficiently acid to cause the denaturation of most proteins and peptides once they are swallowed. Below the stomach level, the proteases from the pancreas like trypsin and chymotrypsin cleave peptide bonds further. This joint process accounts for the 1% to 5% of estimated oral bioavailability for the non-modified peptides consumed normally via capsules, so that most peptides used for therapeutic purposes such as insulin, GLP-1 analogs, and growth hormone are given by injections.

Why BPC-157 May Be an Exception

BPC-157 was originally isolated from a protein in human gastric juice, meaning it evolved in an acidic environment. Published studies suggest that BPC-157 retains structural stability in gastric conditions where other peptides are rapidly destroyed. A 2018 review in Current Pharmaceutical Design noted that BPC-157 has been effective in animal models when administered orally, intraperitoneally and subcutaneously, a versatility not seen with most other research peptides. This gastric stability is a key reason oral BPC-157 products (capsules) exist alongside injectable formats.

Oral Peptide Forms Available for Research

Capsules with Enteric Coating

Enteric-coated capsules are made to withstand breakdown in the acidic environment of the stomach and to release their contents in the more alkaline small intestines (pH 6-7.4). For peptide drugs that are not already stabilized in gastric conditions, the enteric polymer acts as a protective agent against acid degradation. For example, BPC-157 capsules sold by companies like Real Peptides have enteric coating added as an extra measure of stability, even though the BPC-157 peptide has been shown to be stable in the stomach in the published literature.

Sublingual and Buccal Formats

Sublingual administration involves placing drugs underneath the tongue, while buccal administration is where drugs are placed against the inner side of the cheek. These means of drug administration bypass the gastrointestinal tract by allowing direct absorption of drugs through the oral mucosa into the systemic circulation. Though used for some neuropeptides and hormones, they are not used much with BPC-157 since the surface area of the oral mucosa is limited.

Nasal Sprays as an Alternative

The delivery of drugs through nasal sprays avoids first-pass metabolism and the digestive system. Due to the great blood supply and the thin layer of epithelium in the nasal cavity, nasal delivery system for drugs is used mainly for neuropeptides like Semax and Selank which works on the central nervous system. According to some literature on the subject, nasal bioavailability for peptides is between 10% and 30%, which is much greater than that through the oral delivery system but lower than the figure for injections.

Oral vs Injectable: Published Comparisons

Practical Considerations for Oral Peptide Research

Storage Differences for Capsule Forms

Unlike lyophilized vials that require freezer storage and careful reconstitution, oral BPC-157 capsules are typically stable at room temperature in a sealed container away from moisture and direct light. This storage simplicity is one of the practical advantages of capsule forms. However, once a bottle is opened, exposure to humidity can degrade the capsule shell and potentially the peptide inside. Keep capsules in their original sealed container with any included desiccant packet.

Timing and Empty Stomach Protocols in Studies

Animal studies conducted in research experiments usually involve administering oral BPC-157, a peptide, through a process called gavage, which means putting a substance directly into the stomach without considering any food interaction. When human clinical pharmacokinetic data do not exist, most vendors recommend taking BPC-157 capsules on an empty stomach to avoid food-related problems, so it is a kind of extrapolation rather than a scientifically verified recommended usage.